Mössner, Rotraut

[["dc.bibliographiccitation.firstpage","989"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","The Journal of Dermatology"],["dc.bibliographiccitation.lastpage","997"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Loewe, Emilia"],["dc.contributor.author","Schaarschmidt, Marthe‐Lisa"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Gerdes, Sascha"],["dc.contributor.author","Celis, Daniel"],["dc.contributor.author","Poortinga, Sietske"],["dc.contributor.author","Wilsmann‐Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-04-14T08:24:11Z"],["dc.date.available","2021-04-14T08:24:11Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Acrodermatitis continua of Hallopeau (ACH) is a rare chronic inflammatory skin disease. Treatment is extremely challenging and mostly based on empirics as there is only scarce evidence from case reports and few small case series. In this retrospective study, patients with ACH treated at five university medical centers were analyzed according to patient and disease characteristics and treatment experience. We identified 39 patients with ACH with a mean age of 54.4 years at onset, of whom 22 (56.4%) were female. A total of 115 systemic treatment courses were analyzed with methotrexate as the most common therapy (27.0%). Overall, effectiveness of systemic treatments was low (excellent response rate: 14.8%). Among non‐biologics, excellent response was noted in 21.1% (4/19) of treatment courses with methotrexate, followed by acitretin (13.3%; 2/15). Among biologics, guselkumab (excellent response: 100%; 2/2), secukinumab (excellent response: 42.9%; 3/7) and adalimumab (excellent response: 20.0%; 2/10) were most efficacious. The median drug survival was 7.0 months and did not differ significantly between the subgroup of non‐biologic and biologic therapies. To our knowledge, this is the largest case series in ACH investigating patient characteristics and treatment outcomes. Based on our treatment experience, we suggest a treatment algorithm starting with acitretin or methotrexate as first‐line therapy, followed by biologics. Cyclosporin may be used for short‐term control. However, none of the applied systemic therapies yielded satisfying efficacy in our cohort. In patients with primary non‐response, switch of treatment should be evaluated timely on an individual basis, considering possible irreversible disease complications such as nail loss. More research with prospective design is needed to further evaluate traditional and also particularly newer antipsoriatic drugs in ACH."],["dc.identifier.doi","10.1111/1346-8138.15466"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81196"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1346-8138"],["dc.relation.issn","0385-2407"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Treatment of acrodermatitis continua of Hallopeau: A case series of 39 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1441"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","1452"],["dc.bibliographiccitation.volume","20"],["dc.contributor.affiliation","Faverio, Kristin; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Peitsch, Wiebke K.; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Görig, Tatiana; 3\r\nDepartment of Medical Informatics\r\nBiometry and Epidemiology\r\nFriedrich‐Alexander‐University of Erlangen‐Nuremberg\r\nErlangen Germany"],["dc.contributor.affiliation","Schneider‐Burrus, Sylke; 4\r\nCenter for Dermatosurgery\r\nHavelklinik\r\nBerlin Germany"],["dc.contributor.affiliation","Benzel, Friderike; 1\r\nDepartment of Dermatology and Phlebology\r\nVivantes Klinikum im Friedrichshain\r\nBerlin Germany"],["dc.contributor.affiliation","Goebeler, Matthias; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Schummer, Patrick; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Badran, Alaa; 5\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Hospital Würzburg\r\nWürzburg Germany"],["dc.contributor.affiliation","Schaarschmidt, Marthe‐Lisa; 6\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center Mannheim\r\nHeidelberg University\r\nMannheim Germany"],["dc.contributor.affiliation","Harth, Wolfgang; 7\r\nDepartment of Dermatology and Allergology\r\nVivantes Klinikum Spandau\r\nBerlin Germany"],["dc.contributor.affiliation","Mössner, Rotraut; 8\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.author","Faverio, Kristin"],["dc.contributor.author","Peitsch, Wiebke K."],["dc.contributor.author","Görig, Tatiana"],["dc.contributor.author","Schneider‐Burrus, Sylke"],["dc.contributor.author","Benzel, Friderike"],["dc.contributor.author","Goebeler, Matthias"],["dc.contributor.author","Schummer, Patrick"],["dc.contributor.author","Badran, Alaa"],["dc.contributor.author","Schaarschmidt, Marthe‐Lisa"],["dc.contributor.author","Harth, Wolfgang"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2022-12-01T08:31:11Z"],["dc.date.available","2022-12-01T08:31:11Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-27T10:10:51Z"],["dc.description.abstract","Summary\r\n\r\nBackground and Objectives\r\nTreatment options for moderate‐to‐severe hidradenitis suppurativa (HS) comprise antibiotics, biologics, and different surgical methods. These approaches differ substantially regarding the treatment process, success rates, and adverse events. However, information on patient preferences for HS therapies is hitherto scarce. Our aim was to assess patient preferences for medicamentous and surgical treatment of HS with conjoint analysis.\r\n\r\n\r\nPatients and Methods\r\nIn this cross‐section study, computerized discrete choice experiments were used to quantify patient preferences for HS therapies decomposed into treatment modality (tablets, subcutaneous injections, surgery with secondary‐intention healing or primary closure), probability of sustained therapeutic success, probability of mild or severe adverse events, and duration of treatment or wound healing.\r\n\r\n\r\nResults\r\nAveraged over the cohort (n  =  216 patients with HS), sustained therapeutic success was considered as most important (Relative Importance Score [RIS]: 36.2), followed by the treatment modality (RIS: 24.0), and duration of treatment/wound healing (RIS: 19.9), whereas mild or severe adverse events (RIS: 10.7 or 9.3) were regarded as less relevant. Patients preferred tablets, followed by subcutaneous injections, and disliked surgery with primary closure. Preferences differed significantly dependent on age and affected body regions.\r\n\r\n\r\nConclusions\r\nAwareness of patient preferences is essential for patient‐centered care in HS."],["dc.identifier.doi","10.1111/ddg.14886"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118101"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.rights.uri","http://creativecommons.org/licenses/by-nc-nd/4.0/"],["dc.title","Patient Preferences in Hidradenitis Suppurativa (APProach‐HS): a discrete choice experiment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","119"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","127"],["dc.bibliographiccitation.volume","230"],["dc.contributor.author","Wilsmann-Theis, Dagmar"],["dc.contributor.author","Frambach, Yvonne"],["dc.contributor.author","Philipp, Sandra"],["dc.contributor.author","Weyergraf, Ansgar J."],["dc.contributor.author","Jacobi, Arnd"],["dc.contributor.author","Gerdes, Sascha"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2018-11-07T10:03:31Z"],["dc.date.available","2018-11-07T10:03:31Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: In the literature as well as in existing psoriasis guidelines, only little evidence is available on combination regimens with systemic antipsoriatic agents. However, if systemic monotherapy is not efficacious enough to control the disease, a combination therapy might be necessary. Objective:To evaluate the use of fumaric acid esters (FAEs) in combination with other antipsoriatic agents in 6 specialized dermatological departments in Germany. Methods: A systematic retrospective chart review of patients receiving FAEs was performed. Results: A total of 17 cases of patients receiving FAEs combined with at least one other systemic therapy (methotrexate, acitretin, etanercept, cyclosporine, leflunomide and infliximab) to treat psoriasis or psoriatic arthritis were identified. Conclusion: FAEs can be combined in an off-label setting with conventional as well as biological agents to treat recalcitrant psoriasis or psoriatic arthritis. Safety monitoring should be taken seriously as no controlled data for these combination regimens exist. (C) 2015 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000367890"],["dc.identifier.isi","000350267900005"],["dc.identifier.pmid","25661583"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38486"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9832"],["dc.relation.issn","1421-9832"],["dc.relation.issn","1018-8665"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Systemic Antipsoriatic Combination Therapy with Fumaric Acid Esters for Plaque-Type Psoriasis: Report on 17 Cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","447"],["dc.bibliographiccitation.volume","301"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Schmidt, Diane"],["dc.contributor.author","Platzer, Anja"],["dc.contributor.author","Krueger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T08:27:58Z"],["dc.date.available","2018-11-07T08:27:58Z"],["dc.date.issued","2009"],["dc.description.abstract","Serotonin is a monoamine acting as a neuromediator in the central and peripheral nervous system. Recently, serotonin has also been shown to influence T- and B-cell function. The serotonin transporter is central in the regulation of the serotonergic system and widely expressed on cells of the immune system. A functional length polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) has been implicated in the genetic background of depression. Psoriasis is a complex disease with a polygenetic inheritance. In light of the role of T-cell mediated inflammation in psoriasis and the increased prevalence of depression in psoriatic patients, we analyzed the 5-HTTLPR polymorphism in 309 patients with psoriasis vulgaris and 315 healthy control individuals. No significant differences in genotype distribution and allele frequencies were found. There was also no difference in the score of the Hamilton Rating Scale for Depression in patients with psoriasis (n = 137) characterized by carriage of different 5-HTTLPR genotypes. These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients."],["dc.description.sponsorship","Deutscher Psoriasis Bund"],["dc.identifier.doi","10.1007/s00403-008-0909-3"],["dc.identifier.isi","000267389100005"],["dc.identifier.pmid","18979110"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3521"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16317"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","101"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","105"],["dc.bibliographiccitation.volume","300"],["dc.contributor.author","Mössner, Rotraut"],["dc.contributor.author","Thaci, Diamant"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Pätzold, Sylvie"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Krüger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T11:17:20Z"],["dc.date.available","2018-11-07T11:17:20Z"],["dc.date.issued","2008"],["dc.description.abstract","Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been reported. However, paradoxically, manifestation of pustular psoriasis and plaque-type psoriasis has been reported in patients treated with TNF antagonists including infliximab for other indications. Here, we report on 5 patients with chronic plaque-type psoriasis who developed palmoplantar pustulosis during or after discontinuation of infliximab therapy. In two of the five cases, manifestation of palmoplantar pustulosis was not accompanied by worsening of plaque-type psoriasis. Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role."],["dc.identifier.doi","10.1007/s00403-008-0831-8"],["dc.identifier.isi","000253573300001"],["dc.identifier.pmid","18239925"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3520"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54781"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","985"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Nature Genetics"],["dc.bibliographiccitation.lastpage","990"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Strange, Amy"],["dc.contributor.author","Capon, Francesca"],["dc.contributor.author","Spencer, Chris C. A."],["dc.contributor.author","Knight, Jo"],["dc.contributor.author","Weale, Michael E."],["dc.contributor.author","Allen, Michael H."],["dc.contributor.author","Barton, Anne"],["dc.contributor.author","Band, Gavin"],["dc.contributor.author","Bellenguez, Céline"],["dc.contributor.author","Bergboer, Judith G. M."],["dc.contributor.author","Blackwell, Jenefer M."],["dc.contributor.author","Bramon, Elvira"],["dc.contributor.author","Bumpstead, Suzannah J."],["dc.contributor.author","Casas, Juan P."],["dc.contributor.author","Cork, Michael J."],["dc.contributor.author","Corvin, Aiden"],["dc.contributor.author","Deloukas, Panos"],["dc.contributor.author","Dilthey, Alexander"],["dc.contributor.author","Duncanson, Audrey"],["dc.contributor.author","Edkins, Sarah"],["dc.contributor.author","Estivill, Xavier"],["dc.contributor.author","Fitzgerald, Oliver"],["dc.contributor.author","Freeman, Colin"],["dc.contributor.author","Giardina, Emiliano"],["dc.contributor.author","Gray, Emma"],["dc.contributor.author","Hofer, Angelika"],["dc.contributor.author","Hüffmeier, Ulrike"],["dc.contributor.author","Hunt, Sarah E."],["dc.contributor.author","Irvine, Alan D."],["dc.contributor.author","Jankowski, Janusz"],["dc.contributor.author","Kirby, Brian"],["dc.contributor.author","Langford, Cordelia"],["dc.contributor.author","Lascorz, Jesús"],["dc.contributor.author","Leman, Joyce"],["dc.contributor.author","Leslie, Stephen"],["dc.contributor.author","Mallbris, Lotus"],["dc.contributor.author","Markus, Hugh S."],["dc.contributor.author","Mathew, Christopher G."],["dc.contributor.author","McLean, W. H. Irwin"],["dc.contributor.author","McManus, Ross"],["dc.contributor.author","Mössner, Rotraut"],["dc.contributor.author","Moutsianas, Loukas"],["dc.contributor.author","Naluai, Åsa T."],["dc.contributor.author","Nestle, Frank O."],["dc.contributor.author","Novelli, Giuseppe"],["dc.contributor.author","Onoufriadis, Alexandros"],["dc.contributor.author","Palmer, Colin N. A."],["dc.contributor.author","Perricone, Carlo"],["dc.contributor.author","Pirinen, Matti"],["dc.contributor.author","Plomin, Robert"],["dc.contributor.author","Potter, Simon C."],["dc.contributor.author","Pujol, Ramon M."],["dc.contributor.author","Rautanen, Anna"],["dc.contributor.author","Riveira-Munoz, Eva"],["dc.contributor.author","Ryan, Anthony W."],["dc.contributor.author","Salmhofer, Wolfgang"],["dc.contributor.author","Samuelsson, Lena"],["dc.contributor.author","Sawcer, Stephen J."],["dc.contributor.author","Schalkwijk, Joost"],["dc.contributor.author","Smith, Catherine H."],["dc.contributor.author","Ståhle, Mona"],["dc.contributor.author","Su, Zhan"],["dc.contributor.author","Tazi-Ahnini, Rachid"],["dc.contributor.author","Traupe, Heiko"],["dc.contributor.author","Viswanathan, Ananth C."],["dc.contributor.author","Warren, Richard B."],["dc.contributor.author","Weger, Wolfgang"],["dc.contributor.author","Wolk, Katarina"],["dc.contributor.author","Wood, Nicholas"],["dc.contributor.author","Worthington, Jane"],["dc.contributor.author","Young, Helen S."],["dc.contributor.author","Zeeuwen, Patrick L. J. M."],["dc.contributor.author","Hayday, Adrian"],["dc.contributor.author","Burden, A. David"],["dc.contributor.author","Griffiths, Christopher E. M."],["dc.contributor.author","Kere, Juha"],["dc.contributor.author","Reis, André"],["dc.contributor.author","McVean, Gilean"],["dc.contributor.author","Evans, David M."],["dc.contributor.author","Brown, Matthew A."],["dc.contributor.author","Barker, Jonathan N."],["dc.contributor.author","Peltonen, Leena"],["dc.contributor.author","Donnelly, Peter"],["dc.contributor.author","Trembath, Richard C."],["dc.date.accessioned","2019-07-09T11:53:00Z"],["dc.date.available","2019-07-09T11:53:00Z"],["dc.date.issued","2010"],["dc.description.abstract","To identify new susceptibility loci for psoriasis, we undertook a genome-wide association study of 594,224 SNPs in 2,622 individuals with psoriasis and 5,667 controls. We identified associations at eight previously unreported genomic loci. Seven loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA and TYK2). These associations were replicated in 9,079 European samples (six loci with a combined P < 5 × 10−8 and two loci with a combined P < 5 × 10−7). We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 × 10−6). ERAP1 plays an important role in MHC class I peptide processing. ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele. Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis."],["dc.identifier.doi","10.1038/ng.694"],["dc.identifier.fs","574418"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6283"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60315"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Medical Genetics"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Assmann, Gunter"],["dc.contributor.author","Köhm, Michaela"],["dc.contributor.author","Schuster, Volker"],["dc.contributor.author","Behrens, Frank"],["dc.contributor.author","Mössner, Rotraut"],["dc.contributor.author","Magnolo, Nina"],["dc.contributor.author","Oji, Vinzenz"],["dc.contributor.author","Burkhardt, Harald"],["dc.contributor.author","Hüffmeier, Ulrike"],["dc.date.accessioned","2021-04-14T08:26:31Z"],["dc.date.available","2021-04-14T08:26:31Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1186/s12881-020-01037-7"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17317"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81978"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1471-2350"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Genetic variants in FBLIM1 gene do not contribute to SAPHO syndrome and chronic recurrent multifocal osteomyelitis in typical patient groups"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","56"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal of Medical Research"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Patschan, D."],["dc.contributor.author","Sugiarto, N."],["dc.contributor.author","Henze, E."],["dc.contributor.author","Mößner, R."],["dc.contributor.author","Mohr, J."],["dc.contributor.author","Müller, G. A."],["dc.contributor.author","Patschan, S."],["dc.date.accessioned","2019-07-09T11:50:09Z"],["dc.date.available","2019-07-09T11:50:09Z"],["dc.date.issued","2018"],["dc.description.abstract","BACKGROUND: Both psoriasis (Ps) and psoriasis arthritis (PsA) have been associated with increased cardiovascular risk. Also, both are characterized by increased neovascularization. Endothelial progenitor cells (EPCs) have been implicated in promoting vascular repair in ischemic diseases. The aim of the study was to correlate the EPC system with CV risk factors and with parameters of vascular stiffness in Ps and PsA. METHODS: Twenty-six healthy subjects, 30 patients with Ps, and 31 patients PsA were included in the study. eEPC regeneration was evaluated by a colony-forming assay, circulating eEPCs were measured by cytometric analysis. For vascular analysis, all subjects underwent quantification of pulse wave velocity (PWV) and augmentation index (AIX). RESULTS: Patients were categorized upon the duration of disease, severity of skin involvement (PASI-Ps), individual pain as reflected by the VAS (PsA), CRP values, and history of treatment with one or more biologicals. Regarding the eEPC system, no significant differences were observed between the respective categories. Correlation analyses between parameters of vascular stiffness (PWV and AIX) and patterns of colony formation/circulating eEPCs did not show any correlation at all. CONCLUSION: Parameters of vascular stiffness are not significantly deteriorated in Ps/PsA. Thus, pulse wave analysis may not be suitable for CVR assessment in certain autoimmune-mediated diseases. Regenerative activity of the eEPC system/circulating eEPC numbers are not altered in Ps/PsA. One may conclude that malfunctions of the eEPC are not substantially involved in perpetuating the micro-/macrovascular alterations in Ps/PsA."],["dc.identifier.doi","10.1186/s40001-018-0352-7"],["dc.identifier.pmid","30413175"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15871"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59712"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2047-783X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Early endothelial progenitor cells and vascular stiffness in psoriasis and psoriatic arthritis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","353"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","361"],["dc.bibliographiccitation.volume","304"],["dc.contributor.author","Schaefer, Annika"],["dc.contributor.author","Emmert, Steffen"],["dc.contributor.author","Kruppa, Jochen"],["dc.contributor.author","Schubert, Steffen"],["dc.contributor.author","Tzvetkov, Mladen"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Pfoehler, Claudia"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Vogt, Thomas"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Reichrath, Joerg"],["dc.date.accessioned","2018-11-07T09:08:44Z"],["dc.date.available","2018-11-07T09:08:44Z"],["dc.date.issued","2012"],["dc.description.abstract","Melanoma is one of the most aggressive human cancers. The vitamin D system contributes to the pathogenesis and prognosis of malignancies including cutaneous melanoma. An expression of the vitamin D receptor (VDR) and an anti-proliferative effect of vitamin D in melanocytes and melanoma cells have been shown in vitro. Studies examining associations of polymorphisms in genes coding for vitamin D metabolism-related proteins (1 alpha-hydroxylase [CYP27B1], 1,25(OH)(2)D-24hydroxylase [CYP24A1], vitamin D-binding protein [VDBP]) and cancer risk are scarce, especially with respect to melanoma. Mainly VDR polymorphisms regarding melanoma risk and prognosis were examined although other vitamin D metabolism-related genes may also be crucial. In our hospital-based case-control study including 305 melanoma patients and 370 healthy controls single nucleotide polymorphisms in the genes CYP27B1 (rs4646536), CYP24A1 (rs927650), VDBP (rs1155563, rs7041), and VDR (rs757343, rs731236, rs2107301, rs7975232) were analyzed for their association with melanoma risk and prognosis. Except VDR rs731236 and VDR rs2107301, the other six polymorphisms have not been analyzed regarding melanoma before. To further improve the prevention as well as the treatment of melanoma, it is important to identify further genetic markers for melanoma risk as well as prognosis in addition to the crude phenotypic, demographic, and environmental markers used in the clinic today. A panel of genetic risk markers could help to better identify individuals at risk for melanoma development or worse prognosis. We, however, found that none of the polymorphisms tested was associated with melanoma risk as well as prognosis in logistic and linear regression models in our study population."],["dc.identifier.doi","10.1007/s00403-012-1243-3"],["dc.identifier.isi","000305680200003"],["dc.identifier.pmid","22576141"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8093"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26096"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","843"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Vaccines"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Wellmann, Phoebe"],["dc.contributor.author","Siemer, Ralf"],["dc.contributor.author","Klein, Selina"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Pinter, Andreas"],["dc.contributor.author","Wilsmann-Theis, Dagmar"],["dc.contributor.author","Mössner, Rotraut"],["dc.date.accessioned","2021-10-01T09:58:33Z"],["dc.date.available","2021-10-01T09:58:33Z"],["dc.date.issued","2021"],["dc.description.abstract","The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low."],["dc.description.abstract","The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low."],["dc.description.sponsorship","Novartis Pharma"],["dc.identifier.doi","10.3390/vaccines9080843"],["dc.identifier.pii","vaccines9080843"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90088"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.publisher","MDPI"],["dc.relation.eissn","2076-393X"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]